Protalix BioTherapeutics (PLX) EPS (Basic) Growth (1y) (2011 - 2026)
Protalix BioTherapeutics (PLX) EPS (Basic) Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.29 Bn | 132.43 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.58 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 61.87 Bn | 56.73 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.90 Bn | 10.51 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | -16.29% |
| 10 | Protalix BioTherapeutics | 193.17 Mn | 152.51 Mn | 12.13 Mn | 2,164.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,168.87% |
| Mar 31, 2026 | 587.50% |
| Dec 31, 2025 | -130.63% |
| Sep 30, 2025 | -35.50% |
| Jun 30, 2025 | 116.71% |
| Mar 31, 2025 | 24.92% |
| Dec 31, 2024 | 149.98% |
| Sep 30, 2024 | 284.24% |
| Jun 30, 2024 | -112.45% |
| Mar 31, 2024 | -15.50% |
| Dec 31, 2023 | -350.11% |
| Sep 30, 2023 | 64.45% |
| Jun 30, 2023 | 314.15% |
| Mar 31, 2023 | -9.24% |
| Dec 31, 2022 | 55.80% |
| Sep 30, 2022 | 23.56% |
| Jun 30, 2022 | 54.96% |
| Mar 31, 2022 | 66.02% |
| Dec 31, 2021 | -754.81% |
| Sep 30, 2021 | 31.98% |